¹ The FDA and corresponding regulatory authorities will ultimately review our clinical results and determine whether our wholly-owned therapeutic candidates are safe and effective. No regulatory agency has made any such determination that our wholly-owned therapeutic candidates are safe or effective for use by the general public for any indication.

Note: PureTech retains control of Entrega, Inc. and Seaport Therapeutics, and they are consolidated in PureTech’s financial statements. PureTech maintains ownership of equity interests, but does not control, Karuna Therapeutics, Inc., Akili, Inc., Sonde Health, Inc. Vor Biopharma Inc., and Vedanta Biosciences, Inc.
¹ Relevant ownership interests for Vedanta and Sonde were calculated on a partially diluted basis (as opposed to a voting basis) as of December 31, 2023, and Seaport as of April 8, 2024, including outstanding shares, options and warrants, but excluding unallocated shares authorized to be issued pursuant to equity incentive plans. PureTech controls Seaport Therapeutics, Inc. and Gallop Oncology, Inc. Akili and Vor ownerships were calculated on a beneficial ownership basis in accordance with SEC rules as of February 21, 2024 and March 15, 2024, respectively.  
² As of March 22, 2023, PureTech has sold its right to receive a 3% royalty from Karuna to Royalty Pharma on net sales up to $2 billion annually, after which threshold PureTech will receive 67% of the royalty payments and Royalty Pharma will receive 33%. Additionally, under its license agreement with Karuna, PureTech retains the right to receive milestone payments upon the achievement of certain regulatory approvals.

$573.3M

PureTech Level Cash, Cash Equivalents and Short-Term Investments
as of March 31, 2024³

³ PureTech Level Cash, cash equivalents and short-term investments is a Non-IFRS measure.